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Abstract
Background: It is important to quantify the dose response for a drug in phase 2a clinical trials so the optimal doses
can then be selected for subsequent late phase trials. In a phase 2a clinical trial of new lead drug being developed
for the treatment of rheumatoid arthritis (RA), a U-shaped dose response curve was observed. In the light of this result
further research was undertaken to design an efficient phase 2a proof of concept (PoC) trial for a follow-on compound
using the lessons learnt from the lead compound.
Methods: The planned analysis for the Phase 2a trial for GSK123456 was a Bayesian Emax model which assumes the
dose-response relationship follows a monotonic sigmoid “S” shaped curve. This model was found to be suboptimal to
model the U-shaped dose response observed in the data from this trial and alternatives approaches were needed to be
considered for the next compound for which a Normal dynamic linear model (NDLM) is proposed. This paper compares
the statistical properties of the Bayesian Emax model and NDLM model and both models are evaluated using simulation
in the context of adaptive Phase 2a PoC design under a variety of assumed dose response curves: linear, Emax model,
U-shaped model, and flat response.
Results: It is shown that the NDLM method is flexible and can handle a wide variety of dose-responses, including
monotonic and non-monotonic relationships. In comparison to the NDLM model the Emax model excelled with
higher probability of selecting ED90 and smaller average sample size, when the true dose response followed Emax like
curve. In addition, the type I error, probability of incorrectly concluding a drug may work when it does not, is inflated
with the Bayesian NDLM model in all scenarios which would represent a development risk to pharmaceutical
company.
The bias, which is the difference between the estimated effect from the Emax and NDLM models and the simulated
value, is comparable if the true dose response follows a placebo like curve, an Emax like curve, or log linear shape
curve under fixed dose allocation, no adaptive allocation, half adaptive and adaptive scenarios. The bias though is
significantly increased for the Emax model if the true dose response follows a U-shaped curve.
Conclusions: In most cases the Bayesian Emax model works effectively and efficiently, with low bias and good
probability of success in case of monotonic dose response. However, if there is a belief that the dose response
could be non-monotonic then the NDLM is the superior model to assess the dose response.
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Background
An ongoing and serious challenge facing the pharma-
ceutical industry is the high failure rate in the late phase
of drug development [1]. It has been reported that ap-
proximately 50% of Phase 3 clinical trials fail and the
main explanations are the wrong dose being selected or
poor understanding of the dose response in Phase 2 tri-
als [1, 2]. Therefore, it is critical to identify the correct
dose in Phase 2 clinical trials to improve the Phase 3
success rate and thus increase research and development
productivity [3, 4].
An assessment of dose response normally starts with a
linear or nonlinear regression of a drug response for given
doses [5]. Many biological activities follow a 4-parameter
logistic model, and the Emax model is a special case of
the 4-parameter logistic model [3]. Among the possible
dose response models, Emax model is one of the most
widely applied models relating drug concentrations to
effects [3]. In practice, the Emax model assumes the drug
effect is proportional to the dose, i.e. the bigger the dose,
the bigger the effect. Thomas et al. [6] showed that
majority of dose response models in the dose response of
small molecule compounds were Emax models based on
dose response curves from a single company and there
were two cases reported a likely U-shaped dose response
that Emax model failed to fit [6].
As the name implies a U-shaped dose response is a
dose response where there is a down-turn of the clinical
dose-response relationship at higher doses. In the
context of the problem being investigated, we had a
prior belief from a lead compound, where a U-shaped
dose response was observed, that the dose response for
the follow-on compound in the same drug class may
also be U-shaped. For this reason, a U-shaped dose-
response is considered to be pharmacologically plausible
for the follow-on compound as well as for the reason
that a U-shaped dose response had been seen in other
biological treatments for RA [7–10].
There are a number of dose response models available
to handle the non-monotonic U-shaped dose response
relationships [4]. One alternative is the Normal Dynamic
Linear Model (NDLM) which originated in time series
modelling and is a method for model smoothing using
information borrowed from neighbouring doses [11].
Berry [12] then proposed the NDLM model for the
adaptive designs and in the post-herpetic neuralgia trial,
Smith et al. [13] applied a Bayesian NDLM model to a
pharmaceutical drug trial where patients were rando-
mised to a dose based on the dose response model esti-
mated from a posterior distribution. A Bayesian NDLM
model was also used in an Acute Stroke Therapy by In-
hibition of Neutrophils (ASTIN) trial [14]. In the ASTIN
trial patients were allocated 1 of 15 doses, or a placebo,
adaptively based on the response and the study allowed
for early termination for efficacy or futility based on pos-
terior probability using a Bayesian NDLM model. In the
ASTIN trial, a Markov chain Monte Carlo approach was
used to derive a posterior distribution for the model pa-
rameters which informed the estimation of the ED95. In
addition, there have been other applications of NDLM
model such as in in phase 2/3 study for dose selection of
diabetes drug development [15].
For the study being planned there was an interest in the
comparisons of both Emax model and NDLM models for
the dose response assessment in a Phase 2a trial in patients
with rheumatoid arthritis (RA). The Phase 2a trial was ini-
tially designed to investigate the treatment effect of differ-
ent dose levels of GSK123456, using Bayesian Emax model
which was used to guide the Bayesian analysis in searching
for the dose levels targeting at ED90 for future cohorts.
The compound later failed since a U-shaped like curve was
observed in the dose response. The Emax model makes an
assumption of a monotonic dose response relationship
which was seemed to be violated in this trial.
A follow-on compound GSK654321, which is in the
same drug class of GSK123456, is in development. The
chance for GSK654321 having a U-shaped curve cannot
be ruled out, therefore the emphasis of this manuscript
is to find a suitable dose response model and design for
future Phase 2a design of GSK654321, which would pro-
vide reasonable design operating characteristics under
both monotonic dose response and non-monotonic dose
response. In the following section, two main statistical
models (Emax and NDLM) for estimating a dose response
relationship are described and compared in a Phase 2a
trial in patients with rheumatoid arthritis (RA). Also to
use extensive simulations to show how the two models
perform under a fixed and adaptive designs under a
variety of assumed dose-response profiles with a focus on
U-shaped response curve, a pharmacologically plausible
dose response curve in GSK654321.
Methods
Background of clinical trials in RA patients
A primary endpoint of a typical Phase 2 clinical trial is the
change from baseline in DAS28 score. DAS28 is a measure
of disease activity score and the number 28 refers to the
28 joints that are examined in this assessment.
To calculate the DAS28 [16], a clinician will:
1. count the number of swollen joints (out of the 28);
2. count the number of tender joints (out of the 28);
3. take blood to measure the erythrocyte sedimentation
rate (ESR) or C reactive protein (CRP);
4. ask the patient to make a ‘global assessment of health’
(indicated by marking a 10 cm line between very good
and very bad).
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The results from these four domains are then combined
to produce an overall disease activity score ranging from 2
to 10, with a higher score indicating more disease activity.
A DAS28 of greater than 5.1 implies active disease,
less than 3.2 low disease activities, and less than 2.6
as remission.
Bayesian Emax model
The Emax model is a widely applied model relating drug
concentrations to effects [3] and was planned for the
analysis of dose response in the Phase 2a trial.
The Emax model is written as
ΔDAS28 ¼ E0þ Emax
Dose
ED50þ Dose þ ε; ε∼Nð0; σ
2Þ ð1Þ
where ΔDAS28 is the change in DAS28 score from base-
line at day 56 post-randomisation, E0 is the basal effect
corresponding to the response when the drug dose is
equal to 0, Emax is the maximum achievable increase or
decrease over placebo response, ED50 is the dose which
produces 50% of the effect. All the doses were half-log
spaced at design stage with exception of 20 mg/kg. The
maximum dose level across the study cohorts is 30 mg/
kg. The 30 mg/kg dose is the maximum tolerated dose
for the study based on prior studies. If the posterior
mean of ED90 exceeded 30 mg/kg, the maximum
planned dose of 30 mg/kg is used. The priors of model
parameters E0 and Emax follow a Normal distribution
with large variance i.e. N(0,1E4) and the prior distribu-
tion of ED50 are N(3,1E2). The prior on σ2 is an inverse
gamma distribution (IG(0.5,0.7). Markov Chain Monte
Carlo (MCMC) were used to simulate the posteriors dis-
tribution: 2500 samples were used to estimate the model
parameter after burn-in of 500. A larger burn-in was run
and didn’t significantly improve the model fitting and
estimation parameters.
The parameters of interest for the Emax model can be
estimated by maximum likelihood estimation (MLE) and
Bayesian methods – we chose this approach as Bayesian
statistics [17] integrates information into the computa-
tion of the posterior probability of parameters, using the
accumulated data observed so far for later doses and
prior information for the early doses. In addition, the
parameters from Bayesian method are displayed as
distributional profile - which can be useful to illustrate
uncertainty - and offer a robust estimation of parameters
in complicated model [17].
Bayesian normal dynamic linear model (NDLM)
A NDLM can be used to fit to estimate the dose-
response relationship. The description of the NDLM
used in the analysis is shown below,
ΔDAS28jk∼N θj; σ2
 
; ð2Þ
θj ¼ θj−1 þ δj−1 þ ωj;where j ¼ 2;ωj ∼ Nð0; σθ2Þ;
: δj ¼ δj−1 þ vj;where vj ∼ Nð0; σδ2Þ
where ΔDAS28 is the observed individual change in
DAS28 score from baseline at day 56 post-randomisation
at Dosej. The likelihood of DAS28 at day 56 change from
baseline follows a Normal distribution with mean (θj) for
each Dosej and with variance of σ
2, the Dosej is assumed
to be spaced equally. θj is the estimated treatment effect at
Dosej. Furthermore, θj has a linear relationship with
neighboring θj−1 with intercept θj−1 and slope of δj−1. θ1 is
the untreated or placebo response when the drug dose is
equal to 0 and both θ1 and δ1 follow Normal distributions.
Similar to Emax model, the coefficients for the NDLM
model can be estimated from maximum likelihood
methods [18] and Bayesian methods – we used the
Bayesian NDLM method because Bayesian methods offer
robust estimation of parameters with complicated models
and provides better model fitting in both monotonic and
non-monotonic dose response [17].
The prior distribution on θ has a vague Normal distri-
bution with a large variance estimated from inverse-
gamma distribution (IG(0.5, 72). The prior distributions
on σ2 and the evoluation variance σθ
2 and σδ
2 are inverse-
gamma distribution (IG(0.5, 72).
Motivating study
An initial Phase 2a Proof-of-concept (PoC) study was
undertaken to demonstrate whether a new drug,
GSK123456, achieves a certain level of pre-designated
efficacy at a planned dose in RA [19]. The first part (Part
A) of this PoC study was a learning phase with single
dose escalation using a cohort randomised trial [19].
Patients were randomised within each cohort to either
placebo or an active dose of GSK123456. Only the start-
ing dose in cohort 1 was pre-defined and subsequent
doses for other cohorts were selected using a Bayesian
dose response Emax model [19]. A U-shaped dose
response curve for DAS28 change from baseline was
observed with the highest response at 3 mg/kg (Fig. 1).
A consequence of this was the estimation of ED90 was
suboptimal with higher variability.
A dose response in a new class of compound or
target is generally unknown due to the biology and is
not well understood, especially the drug is never being
tested in healthy volunteers or patients. Further phar-
macokinetic and pharmacodynamics data suggests the
U-shaped curve may be due to moderate binding
affinity and rapid off-rate of GSK123456 as compared
to the higher affinity OSM receptor causing a protein
carrier effect [19].
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The follow-on compound GSK654321 is in the same
drug class. It binds to the same binding site as
GSK123456 and it is believed to have therapeutic proper-
ties but with higher potency. Therefore, the chance of U-
shaped dose response cannot be ruled out. It is important
to highlight however that Emax was the pre-specified ana-
lysis. Given the U-shaped curves being pharmacologically
plausible in the follow-on compound GSK654321, there is
a strong desire to compare and adopt a more flexible
model, such as NDLM model, to handle both monotonic
and non-monotonic dose response in the design and
analysis consideration.
We have observed how Emax model was suboptimal in
modelling the dose response. We then applied a model –
NDLM – retrospectively, we know should work for the
observed data and then demonstrated it was superior. For
NDLM to be prospectively planned for GSK654321 there
is need first to do further evaluations of its properties in
the context of a RA PoC study design in the possible
presence of non-monotonicity.
In next sections, we will explore the NDLM model, to
compare the performance of the Emax model and the
NDLM under various assumptions about the shape of
the dose response curves - flat curve, Emax like curve,
Log-linear curve and U-shaped curve.
Simulation
Dose response models in the evaluation
For the simulations four true dose response profiles (Fig. 2)
are used for the primary endpoint, change in DAS28 score
from baseline to day 56, to mimic the wide range of dose
response scenarios likely to be observed and be analysed as
dose response methods in clinical practice. In all models,
the placebo effect (on the background of MTX) was set to
be −0.5. That is a change in DAS28 score from baseline to
day 56 post-randomisation of −0.5 points i.e. a small
decline/improvement is disease activity. The error term ε
was assumed to be independently Normally distributed
with a mean of 0 and a variance of 1.44 for Emax, Log
linear and U-shaped curve, which was the estimated vari-
ance from PoC study of GSK123456 (Fig. 2), the error term
has variance 0.25 for placebo like response.
Profile 1 Flat curve: ΔDAS28 = −0.5 + ε
Profile 2 Emax curve:y ΔDAS28 = −0.5–1.7*Dose/(2.5 + Dose) + ε, ED50
is 2.5.
Profile 3 Log linear curve: ΔDAS28 = −0.5 -log(Dose + 1) + ε
Profile 4 U-shaped curve: ΔDAS28 follows a predefined U shaped curve
with: ΔDAS28 = (−0.5,-0.7,-1.6,-1.8,-1.2,-1, −0.6) for
dose 0, 0.03, 0.3, 3, 10, 20, and 30 mg/kg respectively.
These four profiles were chosen as plausible dose
responses for the new compound in development
GSK654321 ranging from a null effect (Profile 1) to what
was previously observed with GSK123456 (Profile 4).
The scenarios of fixed design simulation and adaptive
design simulation are discussed in the next section. The
two basic designs set up are a fixed design and an adaptive
design. The fixed design assumes that all six doses and
placebo are allocated to a fixed number of patients. No
adaptations are adopted in this design. In the adaptive
design, the subjects are allocated according to the dose
responses of all the subjects enrolled in the study.
Fig. 1 Mean and estimated dose response of mean change in DAS28 scores from baseline using Bayesian Emax and NDLM models. The mean
changes in DAS28 score between the doses were connected with a straight line in solid blue lines; the data are for illustration purpose so the
error bars are not presented. Emax model is displayed as red dash/dotted line and NDLM model as green dotted line
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Design of the Simulation Study
The range of doses is between 0.03 mg/kg to 30 mg/kg.
The design is a parallel design and the total target
sample size is 64. The goal of the trial is to characterise
the dose-response curve at various doses. The fixed
design assumes that all 6 doses are allocated to a fixed
number of patients with no interim analysis or adapta-
tion of the dose. In the adaptive simulation, the subjects
are allocated due to the subjects’ response in the study
at the end of each cohort.
Decisions regarding success and futility of the trial at
completion are made based on the probability of DAS28
relative to control greater than clinically significant
difference (a decrease of 0.95 as measured by DAS28
change from baseline between placebo and treatment).
The positive difference of placebo and treatment is used
to facilitate the positive effect and probability calculation.
All the designs except fixed scenarios include 8 cohorts,
with 8 patients in each cohort (2 on placebo and 6 on
active treatment).
An adaptive design was used in the PoC design of
GSK123456 and is considered as a better option than
fixed design since it increases the chance of stopping a
failed compound and expediting a good one as well as
potentially maximizing the information on the doses
which are most interest to carry forward for later
development. For GSK654321 the study design has not
been finalised. The wish therefore was to evaluate
modelling the dose response using NDLM or Emax for
different options for the study design which we have
detailed. The follow-on compound GSK654321 is in the
same drug class as GSK123456 which demonstrated
good safety and tolerability in the PoC study [19], so
there is no single dose escalation planned for the PoC
study in GSK654321.
ED90 is defined as the dose to achieve 90% of
maximum DAS28 response with the lower dose chosen
if there are multiple values. In this calculation the
maximum response is estimated from the maximal
DAS28 effect at all doses. The 90% (ED90) of maximum
response is then calculated as the lowest nominal dose
in which is closest to the estimated dose that achieves
90% of maximal efficacy. The following fixed design as
well as adaptive design scenarios are considered in the
design options and evaluations.
Scenario 1 Fixed design; the design is non-adaptive, the study allo-
cates 8 patients to receive doses of GAK654321 (0.03, 0.3, 3,
10, 20 and 30 mg/kg) and 16 patients to receive placebo.
There is no interim stopping and adaptation in the fixed
design. The evaluation of final success will occur at the end
of the study.
Scenario 2 No adaptive allocation; the ratio of patients (100% of the
planned sample size) randomized into each study dose
(placebo, 0.03, 0.3, 3, 10, 20 and 30 mg/kg) are 2:1:1:1:1:1:1.
The placebo is given to a fixed proportion of the sample
size allocation to ensure there is enough power for
treatment comparisons vs. placebo. There are a total of 8
cohorts (6 treated +2 placebo) and the interim analysis will
occur between cohorts, for example, at 8 patients, 16
patients, 24 patients, 32 patients (50%), 40 patients (62.5%)
and 48 patients (75%) enrolled and complete the primary
endpoint assessment (day 56 post-randomisation DAS28
score). The study is evaluated with the interim study success
and interim study futility.
Fig. 2 The four true Dose-response profiles used in the simulations. The model profiles include a placebo like flat curve which is denoted in blue
and is fixed at −0.5 for all dose levels, a dose proportional Emax model in red, a log-linear model in green, and a U-Shaped model in purple. The
label for the vertical axis is the change in DAS28 score from predose at day 56 post-randomisation
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Scenario 3 Half adaptive, the first 50% of subjects are fixed allocated
using pre-defined allocation ratio of treatments and placebo
followed by adaptive allocation for the rest of the subjects
based on the posterior distribution of dose around ED90;
the placebo is given to a fixed proportion of the sample size
allocation to ensure we have enough power for treatment
comparisons vs. placebo. The fixed proportion is 25% of the
total sample size. For each study dose (0.03, 0.3, 3, 10, 20 and
30 mg/kg), the 4 patients (50% of the planned sample size)
will be randomized first, prior to any interim analysis. The dose
response curve will then be fitted using the dose response
model and ED90 is estimated. For each subject randomised
into the study afterwards, the dose level will be randomized
to the dose close to the ED90 dose response. The interim ana-
lysis will occur at 32 patients (50%), 40 patients (62.5%) and 48
patients (75%) that complete the primary endpoint assess-
ment. The study is evaluated for interim study success and in-
terim study futility.
Scenario 4 Adaptive allocation after the first cohort. In the fully adaptive
simulation, the placebo is given a fixed proportion of the
sample size allocation to ensure there is enough power for
treatment comparisons vs. placebo. The fixed proportion is
25% of the total sample size. The dose response curve will be
fitted using the dose response model and ED90 is estimated.
For each subject randomised into the study afterwards, the
dose level will be randomized to the dose close to ED90 dose
response. The interim analysis will occur between cohorts, for
example, at 8 patients, 16 patients, 24 patients, 32 patients
(50%), 40 patients (62.5%) and 48 patients (75%) enrolled and
complete the primary endpoint assessment. The study is
evaluated for interim study success and interim study futility.
The simulation and analysis are performed using a data
simulation and analysis software - FACTs (Fixed and
Adaptive Clinical Trial Simulator) version 2.1 and 4.05
developed by Tessella and Berry Consultant. Simulated
data are fitted using similar Emax model and NDLM
models as described in Eqs. 1 and 2. It is possible that the
choice of informative prior impacts the simulation results
[20], for consistency and comparison purpose, a vague
prior is chosen in the calculation and simulation. The
priors for the Emax model parameters Eo and Emax are
vague and follow a Normal distribution with large variance.
Thus, the prior of model parameter E0 is N(0,1E4) and the
prior distribution of ED50 is N(3,1E2). The vague prior
distribution of evolution variance for NDLM model is
inverse-gamma distribution (IG(0.5, 72). Additionally, se-
lected informative priors are explored in the simulations.
The simulation starts with fixed seed and all results are
based on 5000 simulations. The number of simulations and
number of MCMC simulations as 2500 with burn-in of 500
are chosen based on the estimated minimum precision.
Decision criteria in adaptive design simulation
Decision criteria for interim success, interim futility,
final success and final futility in the adaptive design
simulation are displayed in Table 1. For the fixed design,
the final success is based on at least 95% posterior
probability that the dED90 dose achieves a drug effect
greater than the control or placebo, otherwise it is final
futility. For all other adaptive design (scenario 2, 3, and
4), the decision criteria of the interim success, interim
futility, final success and futility are presented in Table 1.
When there is truly is no effect or a placebo like
effect, the Type I error rate is calculated based on the
chance of rejecting the null hypothesis (when it is true).
In the context of this simulation it would also be the
chance of incorrectly accepting that the drug has a dose
response, the false positive rate, and the statistical bias.
Results
Design comparisons using simulation
The results from the simulations giving the probability
of interim and final success and failure in fixed design
(S1), no adaptive allocation (S2), half-adaptive (S3) and
fully adaptive (S4) using Bayesian Emax model and
NDLM model are displayed in Table 2.
For Emax like true dose response, the total probability
of success is 98% and 98% in fixed design; 93% vs. 91%
in No-Adaptive Allocation design, 99% vs. 97% under
Half Adaptive scenario and 95% vs. 96% under Adaptive
Allocation scenario for Emax and NDLM models re-
spectively. The average sample sizes in the trials are less
in the No-Adaptive Allocation design, half adaptive and
adaptive design than fixed design. Similar results and
trends are also shown for log linear dose response curve.
The Type I error is inflated in Bayesian NDLM model in
all scenarios under the current prior. The higher Type I
error could potentially lead to a false investment decision
and further work when a compound does not truly have
an effect. Though the inflation of type I error rate is not a
regulatory risk for a Phase 2a study it is a potential risk to
the sponsor. The Phase 2a study is still an investigative
study so the consequences risks are less and once the final
study design is established the simulations will need to be
reinvestigated with the decision criteria (as described in
Table 1) set so the Type I error is controlled.
Table 3 displays the additional operating characteristics
of the model fitting to the data that were analysed using
the Emax model and NDLM model for Half Adaptive (S3)
design. The proportion of times the dose being selected as
ED90 are displayed with each of the four curves. The
ED90 of the true Emax curve is likely to be between 20
and 30 mg/kg. Similar results for No adaptive (S2)
and fully adaptive (S4) are presented in Additional file 1:
Table S1 and Table S2 respectively.
Results from the simulations show that the Bayesian
Emax model is able to find the correct dose for ED90
almost 100% of time (proportion of ED90 as 20 and
30 mg/kg) when the true response is either an Emax
curve or log linear curve, comparing to approximately
61%–83% using Bayesian NDLM model. If the true dose
response relationship is assumed to follow a U-shaped
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Table 1 Decision criteria at the interim analysis and final analysis in the proposed design scenarios
Decision Criteria Interim Success Interim Futility Final Success Final Futility
Pr(|RED90 –Ctrl| > 0) >95% <20%
Pr(|RED90 –Ctrl| > 0.95) >70%
Pr(|Rdmax –Ctrl| > 0) > 0.95 and Pr(|RED90 –Ctrl| > 0) >95% Yes No
Pr(|RED90 –Ctrl| > 0): The probability of dose response near ED90 dose level achieves a drug effect greater than the control or placebo
Pr(|RED90 –Ctrl| > 0.95): The probability of dose response near ED90 dose level achieves a drug effect greater than the control or placebo and 0.95 is the clinical
significant difference
Pr(|Rdmax –Ctrl| > 0): The probability of any dose with maximal effect achieves a drug effect greater than the control or placebo
Only final success and futility are accessed in fixed design
Table 2 Probability of success and failures at interim and final analysis at fixed and adaptive design scenarios
True Dose Response Design Scenarios Models Comparisons Early
success
Early
failure
Final
success
Final
failure
Total
Success
Mean
subjects
Placebo like flat curve Fixed Design (S1) Bayesian Emax – – 0.06 0.94 0.06 64
Bayesian NDLM – – 0.17 0.83 0.17 64
No Adaptive design (S2) Bayesian Emax 0.00 0.39 0.04 0.57 0.04 51
Bayesian NDLM 0.03 0.03 0.16 0.78 0.18 58
Half Adaptive design (S3) Bayesian Emax 0.00 0.23 0.04 0.73 0.04 61
Bayesian NDLM 0.00 0.00 0.12 0.88 0.12 64
Adaptive (S4) Bayesian Emax 0.03 0.39 0.04 0.54 0.07 55
Bayesian NDLM 0.01 0.01 0.12 0.86 0.13 64
Emax curve Fixed Design (S1) Bayesian Emax – – 0.98 0.02 0.98 64
Bayesian NDLM – – 0.98 0.02 0.98 64
No Adaptive design (S2) Bayesian Emax 0.74 0.03 0.19 0.04 0.93 38
Bayesian NDLM 0.82 0.01 0.09 0.08 0.91 37
Half Adaptive design (S3) Bayesian Emax 0.74 0.00 0.26 0.01 0.99 55
Bayesian NDLM 0.53 0.00 0.44 0.03 0.97 57
Adaptive (S4) Bayesian Emax 0.80 0.03 0.15 0.02 0.95 42
Bayesian NDLM 0.55 0.00 0.41 0.04 0.96 56
Log Linear Curve Fixed Design (S1) Bayesian Emax – – 0.96 0.04 0.96 64
Bayesian NDLM – – 0.95 0.05 0.95 64
No Adaptive design (S2) Bayesian Emax 0.64 0.05 0.24 0.08 0.88 40
Bayesian NDLM 0.74 0.00 0.15 0.11 0.89 40
Half Adaptive design (S3) Bayesian Emax 0.58 0.00 0.40 0.02 0.98 57
Bayesian NDLM 0.45 0.00 0.47 0.08 0.92 58
Adaptive (S4) Bayesian Emax 0.70 0.03 0.24 0.03 0.94 45
Bayesian NDLM 0.51 0.00 0.43 0.06 0.94 56
U-Shaped curve Fixed Design (S1) Bayesian Emax – – 0.26 0.74 0.26 64
Bayesian NDLM – – 0.92 0.08 0.92 64
No Adaptive design (S2) Bayesian Emax 0.10 0.26 0.14 0.50 0.24 47
Bayesian NDLM 0.63 0.01 0.17 0.18 0.80 43
Half Adaptive design (S3) Bayesian Emax 0.06 0.09 0.10 0.75 0.16 62
Bayesian NDLM 0.41 0.00 0.47 0.12 0.88 59
Adaptive (S4) Bayesian Emax 0.14 0.24 0.10 0.52 0.24 54
Bayesian NDLM 0.42 0.00 0.44 0.14 0.86 58
Liu et al. BMC Medical Research Methodology  (2017) 17:149 Page 7 of 14
curve, the proportion of simulations selecting the ED90
as 0.3 and 3 mg/kg are 0% vs 82% in non-adaptive
design, 0% vs 90% in Half-adaptive setting and 0% vs
91% in Adaptive setting using Emax model and NDLM
model respectively when the true ED90 is around
2.5 mg/kg. NDLM is able to identify the correct ED90
doses 58% or 76% of the time when the true response is
an Emax or log linear curve respectively.
All the simulated results seem to indicate that the
Emax model performs better when the dose responses
are monotonic and the NDLM model is a more robust
approach in all four types of model and is superior to
identify the correct ED90 doses when the true response
followed a U−shaped curve.
In earlier comparisons of the Emax and NDLM models,
the same decision rules were applied and to assess the type
I errors. To facilitate for a fair comparison of power
without the need for recalibrating type I error at each
design, Receiver Operating Characteristic curves (ROC
curve) for the fixed design (S1) and half-adaptive (S3) are
presented in Figs. 3 and 4 respectively. The ROC curves
Table 3 Proportion of doses being selected as ED90 of
Bayesian Emax and NDLM model at different dose response
curves in the Half Adaptive design settings (Scenario 3)
Dose Level (mg/kg)
0.03 0.3 3 10 20 30
Bayesian Emax Model
Proportion of doses being selected as ED90
Flat placebo like Curvea 0% 0% 0% 0% 38% 0%
Emax like Curve 0% 0% 0% 0% 89% 11%
Log Linear Curve 0% 0% 0% 0% 81% 19%
U-Shape Curvea 0% 0% 0% 0% 64% 0%
Bayesian NDLM Model
Proportion of doses being selected as ED90
Flat placebo like curve 16% 17% 14% 14% 11% 12%
Emax like Curve 1% 1% 14% 25% 35% 26%
Log Linear Curve 1% 1% 5% 11% 29% 54%
U-Shape Curve 2% 42% 48% 5% 2% 0%
aED90 is missing where the maximum dose was not estimated correctly
a
c
b
Fig. 3 Receiver operating characteristic ROC curve display the true positive rate (statistical power) and false positive rate for Bayesian Emax (red)
and NDLM model (blue) under Fixed design (S1). Bayesian Emax (blue dashed line) and NDLM model (red solid line) and dose response following
a U-Shaped, b Emax or c Loglinear curve
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draw a plot of the true positive rate against the false posi-
tive rate for the different possible decision criteria. Since
any increase in sensitivity is accompanied by a decrease in
specificity, the ROC shows the tradeoff between sensitivity
and specificity. For each design, the true positive rates from
Bayesian Emax and NDLM model at assumed U-shaped,
Emax or Loglinear curves are plotted against the corre-
sponding false positive rates from flat curve. The closer the
curve follows the left border and the top border of the
ROC space, it shows the better sensitivity given specificity.
Similar ROC curves for non-adaptive (S2) and adaptive
(S4) design are presented in supplemental material.
Under half adaptive design, the ROC curve of Bayesian
Emax model is closer to the left and top borders than
NDLM model when the assumed curves follow Emax or
loglinear curves, so Emax model performs better. When
the type I error rate is at 5%, the true positive rate of to
Bayesain Emax model is approximately at 97% for both
Emax curve and loglinear curve and the true positive rate
is 90% and 85% for both Emax curve and loglinear curve
using NDLM model. For U-shaped curve, the Bayesian
NDLM model performed better than Emax model. The
results are in line with earlier conclusion that Emax model
outperforms if dose response is monotonical and NDLM
model is better when the dose response is U-shaped.
Assessment of bias
The assessment of statistical bias through simulation at
each dose level (placebo, 0.03, 0.3, 3, 10, 20, and 30 mg/kg)
is calculated as the difference in the estimated mean
response using Emax or NDLM models against the
assumed true response profile (at each dose level). The
difference from the true dose response profile is estimated
for each simulation. The mean difference - and bias - is
taken as the mean difference for the dose response from
the truth across all 5000 simulations.
The Bayesian Emax model is compared to the NDLM
model under four profiles of true dose response being
Emax curve (Fig. 3a), flat curve (Fig. 3b), log linear
curve (Fig. 3c), and U-shaped curve (Fig. 3d) for each of
the four design scenarios: fixed design, no adaptive (S2),
half adaptive (S3) and fully adaptive (S4).
Under the fixed design and no adaptive allocation and
assumption of true dose response as Emax like curve
Fig. 4 Receiver operating characteristic ROC curves display the true positive rate (statistical power) and false positive rate for Bayesian Emax (red)
and NDLM model (blue) under Half adaptive design (S3). Bayesian Emax (blue dashed line) and NDLM model (red solid line) and dose response
following a U-Shaped, b Emax or c Loglinear curve
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(Fig. 5a) or log linear (Fig. 5c) shape curve, there is
less bias (absolute bias) of mean response at lower
dose levels using the NDLM model in comparison to the
Bayesian Emax model. The bias using Emax model is less if
the true dose response data follow a placebo like response
(Fig. 5b) than NDLM model and the absolute values of all
bias are less than 0.02. If the true dose response curve is a
U Shaped non-monotonic curve (Fig. 5d), the bias is much
bigger at 0.3 mg/kg and 3 mg/kg if analysing using the
Emax model (0.6510 in Emax model vs. -0.0062 at
0.3 mg/kg in the NDLM model; 0.7523 in Emax model vs.
0.0155 at 3 mg/kg in the NDLM model), since the Emax
model makes the assumption of monotonic changes and
still fits the line between the lowest dose and highest dose,
ignoring the U-shaped response.
Under the half adaptive allocation design and the
assumption of true dose response as an Emax like curve
or log linear shape curve, similar to fixed design, there
are less bias (absolute bias) of mean response at lower
dose levels but more bias at 20 mg/kg using the NDLM
model in comparison to the Bayesian Emax model. The
individual bias from each dose level shows that Emax
model tends to underestimate the dose response effect
while NDLM tends to overestimate the effect in the mean
response. The bias using Emax model is less if the true
dose response data follow a placebo like response than
NDLM model and the absolute values of all bias are less
than 0.06. If the true dose response curve is a U-Shaped
non-monotonic curve, the bias is much bigger at
0.3 mg/kg and 3 mg/kg if analysing using the Emax
model (0.7182 in Emax model vs. 0.0656 at 0.3 mg/kg
in the NDLM model; 0.8835 in Emax model vs. 0.0992 at
3 mg/kg in the NDLM model) for the same reason de-
scribed earlier.
Under the fully adaptive allocation design and the
assumption of the true dose response as an Emax like
b d
a c
Fig. 5 The statistical bias based on the fixed Design and design with adaptations. The statistical bias is based on each planned dose group
(placebo, 0.03, 3, 10, 20, and 30 mg/kg) under four scenarios of design setting as fixed design, no adaptive (Scenario 2), half adaptive (Scenario 3)
and fully adaptive (Scenario 4). The true dose responses follow dose profiles of a: Emax curve; b: flat curve; c: log linear curve and d: U-shaped curve
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curve, the bias of the Bayesian Emax model and NDLM
model is similar. The individual bias from each dose level
shows that Emax model tends to underestimate the mean
response effect at 0.03, 0.3 and 30 mg/kg while NDLM
tends to overestimate the effect at 3 and 20 mg/kg in the
mean response. The biases are also similar if the true dose
response data follow a log linear curve and Emax model
tends to underestimate the mean response while NDLM
tends to overestimate the mean response. NDLM model
also overestimate the mean response if the true response
is placebo like curve. If the true dose response curve is a
U-Shaped non-monotonic curve, the bias is much bigger
at 0.3 mg/kg and 3 mg/kg if analysing using the Emax
model (0.8013 in Emax model vs. 0.1170 at 0.3 mg/kg in
the NDLM model; 0.9678 in Emax model vs. 0.1553 at
3 mg/kg in the NDLM model).
Amongst all the designs, a hybrid approach of half
adaptive design with fixed allocation at 50% subjects
before any adaptive allocation seems to have the most
reasonable operating characteristics and will be
considered to carry forward for GSK654321. To further
explore the impact of the analysis methods additional
simulations were undertaken to examine the impact of
choice of informative priors but anchored in the single
half adaptive design (S3). The results for the Emax
model are given below in Table 4.
The probability of success, as measure of posteriors
probability of treatment effect (difference between
treatment and placebo) greater than zero, increased in
all dose response curves with 100%, 99, 59% success if
the dose response follows a Emax model, Loglinear
model and U-shaped curve. The type I error rate is
inflated to 8% in Emax model with the informative prior.
This inflated type I error rate would need to be commu-
nicated to the study team who may consider this to be
too high a development risk.
Additional simulations for the NDLM model were
performed to examine the impact of informative prior
on the half adaptive design (S3) and are displayed below
with two prior choices a) the evolution variance has
prior of Inverse Gamma (IG) distribution (IG(0.5,0.5))
and b) IG(2,4).
The additional simulations seem to show that the
NDLM model fitting is sensitive to the choice of evolution
variance and the probably of success and type I error are
impacted by the choice of priors such that with an
informative prior, type I error was reduced to as low as 7%
with little impact of the probability of success in other
dose response curve. These considerations need to be
weighed up by the study team. If the Type I error is
important then the priors may be further investigated to
reduce these to an acceptable level.
To compare the goodness of model fitting, deviance
information criteria (DIC) results were calculated for
both Emax and NDLM model based on dataset from
single simulation in Half adaptive design. DIC was
penalized for overfitting with additional parameters in
the model. The DIC for NDLM model was 181.1 in
comparison to 187.0 for Emax model, which further
showed that there was no overfitting in NDLM model.
Summary of model comparison: Emax model versus
NDLM model
If dose response follows a monotonic response i.e. Emax
or log linear curve, both Bayesian Emax and NDLM
models have good operating characteristic in the
probability of success at interim and final analysis.
However, a Bayesian Emax model performs better with
higher probability of success than NDLM model in all
the scenarios.
If the dose effects change non-monotonically in a
U-shaped dose response curve, the power measured
as the probability of success of the Bayesian Emax
model is 26% vs 92% using the NDLM model in fixed
design, 24% vs 80% in No-adaptive design, 16% vs
88% in Half-Adaptive design and 24% vs 86% in
Adaptive design. The NDLM model significantly improves
the probability of success compared to the Emax model in
all four design simulations.
Under the same decision criteria, the Type I error
rates are elevated to 12% for half-adaptive or fully adap-
tive scenario and to 18% for a non-adaptive scenario
when analysing using the NDLM model, while the type I
error is generally under control below 5% using Emax
Table 4 Probability of success and failures at interim and final analysis with Bayesian Emax model with informative prior
(β1 ~ N(−0.5, 1.2*1.2), β2 ~ N(−2.9, 1.2*1.2) and β3 ~ N(3, 2*2), β1, β2, and β3 are parameter estimates of E0, Emax and ED50
respectively) in the half adaptive design (Scenario 3)
True Dose Response Bayesian Emax model
Early success Early failure Final success Final failure Total Success Mean subjects
Placebo like flat Curve 0.00 0.13 0.08 0.79 8% 63
Emax Curve 0.87 0.00 0.13 0.00 100% 51
Log Linear Curve 0.71 0.00 0.28 0.01 99% 54
U-Shaped Curve 0.18 0.00 0.41 0.40 59% 61
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model. An inflated Type I error rate signals that the
NDLM model is over-sensitive and is thus inflating the
number of false positive trials. When controlling Type I
error, it was shown from ROC curves that the statistical
power is 8–10% lowers in NDLM model if the dose
response follows Emax or Loglinear curves but much
better in case of U-shaped curve. Analysis of the NDLM
model led to a significant increase in the statistical
power of detecting the treatment difference, when the
true dose response is non-monotonic, compared to the
Bayesian Emax Model. The probability of success using
NDLM model was similar regardless of which under-
lying true dose-response profile was assumed, but less
sensitivity in the analysis of selecting the dose response
of ED90 and an increase in the statistical bias, compared
to the Bayesian Emax model. The Bayesian Emax model
excelled with a higher probability of selecting ED90 and a
smaller average sample size, when the true dose response
followed Emax like curve, compared to NDLM model.
Though there were some variations, the bias is
comparable if the true dose response follows a placebo
like curve, Emax like curve, or log linear shape curve
under the no adaptive allocation, half adaptive and
adaptive scenarios. The bias for Emax is significantly
increased if the true dose response is assumed to follow
a U-shaped non-monotonic curve.
Discussion
Due to the fact that the results for a PoC RA study of a
drug in the same class followed a U-shaped dose response
there was a wish to investigate if the analysis could be
improved for a new compound in development. Of
particular interest, in context with the development for
GSK654321, the NDLM model was able to maintain the
probability of success even in the case of a non-
monotonic dose response.
We were conscious that the design of GSK654321 was
driven by a single study for a lead compound, GSK123456,
the analysis of which seemed to show a U-shaped dose
response and the U-shaped dose response was deemed
pharmacologically plausible [19]. Given the limitations
of the NDLM model when the response is not U-shaped
we decided to undertake further investigations of the
U-shaped dose response in a literature review to assess the
likelihood - based on the literature - of seeing this dose
response relationship. It is shown that it is plausible to
observe a U-shaped curve in the study with RA patients
[21, 22]. Thomas et al. [6] showed that in the majority of
cases the observed means could be well described using a
Bayesian Emax model and Emax is one of the best models
to estimate the dose response if data follows Emax curve,
however, while biological exposure response relationships
are often monotonic, down-turns of the clinical dose-
response relationship at higher doses have been observed,
one example in biologics development is the immunogen-
icity observed at high dose in the patients treating with bio-
logicals. Therefore, we recommend to routinely consider a
U-shaped dose-response model unless U-shaped profiles
can be excluded with certainty at the trial design stage.
The work in this manuscript was inspired by the PoC
design of the follow-on compound after the U-shaped
curve was found in earlier clinical trial, which Bayesian
Emax model was used. We aim to compare it with a
more flexible NDLM model in the PoC design of the
follow-on compound. Systematic literature search was
conducted in the databases Google scholar, PubMED
and web of science (WoS) and there was limited existing
Literature in the comparison of Emax and NDLM model.
Work by Jane Temple [23, 24] was deemed relevant but,
within the parameters of the simulation undertaken by the
authors although the research of Temple was of interest
the work could not be generalised to the study being
Table 5 Probability of success and failures at interim and final analysis with Bayesian NDLM model with informative prior in the half
adaptive design (Scenario 3)
True Dose Response Bayesian NDLM model
Early success Early failure Final success Final failure Total Success Mean subjects
a) evolution variance ~IG(0.5,0.5), initial dose ~N(−0.5, 1.2*1.2)
Placebo like flat Curve 0.00 0.01 0.07 0.92 0.07 64
Emax Curve 0.71 0.00 0.28 0.11 0.99 58
Log Linear Curve 0.69 0.00 0.28 0.03 0.97 57
U-Shaped Curve 0.34 0.00 0.51 0.15 0.85 62
b) evolution variance ~IG (2,4), initial dose ~N(−0.5, 1.2*1.2)
Placebo like flat curve 0.00 0.00 0.10 0.90 0.10 64
Emax Curve 0.74 0.00 0.24 0.02 0.98 58
Log Linear Curve 0.70 0.00 0.26 0.03 0.96 57
U-Shaped curve 0.49 0.00 0.40 0.10 0.89 60
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planned and described in this paper. This work demon-
strated that both Bayesian NDLM model and Emax model
detect a dose response well but Bayesian NDLM
tends to have the highest power in the probability of
detecting a clinical response than Emax model in the
non-monotonical dose response.
It was also shown in the research of Temple that
Bayesian NDLM tended to underestimate the response
at lower doses, therefore resulting in higher doses being
selected, however, our simulation showed a similar or
better model fitting in Bayesian NDLM model than
Emax model within the context of Phase 2a design. In
addition, we found out that the adaptive design being
proposed seemed to perform better with smaller average
sample size but there was little difference in different
allocation methods using NDLM model. These results
agree with the finding in Temple [23, 24].
It has been reported that a Bayesian logistic model,
especially with hierarchical longitudinal modelling with
unbounded priors, often does not converge well [25, 26],
posing a significant risk to dose escalation analysis.
However, the NDLM model is a good alternative to the
Emax model at the expense of pharmacological meaning
in model parameters like maximal response Emax and
ED50. This is to use an alternative, less complicated,
modelling such as the linear model, power model etc. or
a non-parametric model, such as the spline model or
NDLM model. This will reduce the risk of non-
convergence. A more Informative distribution on priors
that constrain the parameter space to reasonable values
would help the convergence for both models [27].
The main cause for concern with NDLM was the
inflation of the Type I error. To minimise this problem,
the decision criteria or informative prior may need to be
adjusted to control the Type I error if the same decision
rules are used in the comparison. After controlling for
the type I error rate at 5%, the statistical powers of
Emax model are ~8% higher than that of NDLM models
in Emax and Log-linear dose responses, which was
further supported by ROC results. The NDLM model
works better when dose response follows U-shaped
curve. Further work would be required therefore for any
individual study to optimise the design characteristics. It
is also acknowledged that NDLM model did not have
high specificity in finding ED90 compared with the
Emax model when the data follow Emax model.
It should be noted that the methods described in this
paper were anchored in a single RA example with the
simulations and results presented only applicable to this
case study which motivated our work. This is of
particular importance if different dose responses are
anticipated or are of importance for an evaluation. Even
for this case study there would be a need for further
work once the study design has been finalised. In cases
where a U-shaped curve is expected or there is potential
physiological/pharmacological rationale of down-turn
response, Bayesian NDLM model is generally recom-
mended and this conclusion can be generalized to
other case studies. In addition, our methods of evalu-
ation in finding the best design could be generalised
to other clinical trials to offer a solution to expedite
drug development.
Conclusion
An adaptive design, especially a half-adaptive design, is
more a efficient design than a fixed design due to an
increased chance of a dose being selected being the ED90
dose and due to the reduced s average sample size being
use in the clinical trial. In most cases the Bayesian Emax
model works effectively and efficiently, with low bias and
good probability of success when there is a monotonic
dose response. However, if there is a belief that the dose
response could be non-monotonic based on prior know-
ledge as in our case study - where a compound in the
same class seemed to have non-monotonic dose responses
- then the NDLM is the superior model to assess the dose
response. Within the parameters of the simulation the
NDLM model was shown to be flexible with the ability to
handle a wide variety of dose-responses, including mono-
tonic and non-monotonic relationships.
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